With more than 25 years of experience in management positions in the pharmaceutical industry (HMR, now Sanofi), Dr. Dominique Costantini has overseen many therapeutic innovations and was involved in the development of numerous medicines, from conception to product approval and commercialisation (notably in immunology, oncology, endocrinology and infectious illnesses).

In 1997, Dominique Costantini founded and led as CEO BioAlliance Pharma (now Onxeo), a biotech company in oncology and supportive care; in 2005, she conducted the company’s IPO on Euronext and the registration of products in Europe and the US.

In 2012, Dominique founded and was CEO of OSE Pharma, a biotech company in cancer immunotherapy. In 2015, she conducted the company’s IPO on Euronext and in 2016 its merger with Effimune, a biotechnology company specialized in immune regulation. Dominique served as CEO and Director of the company, since renamed OSE Immunotherapeutics until April 2018.

Dr. Dominique Costantini is a Medical Doctor (Paris V University), specializing in immunology.

Alexis Peyroles has more than 20 years of international management and financial control experience, having served in multiple related positions. He joined Sanofi-Aventis in 1996 as Financial Controller in Japan before becoming Head of Financial Control for the Baltic States. He was subsequently named Head of activities for Business Development in Eastern Europe. In 2005, Alexis joined the Guerbet group (a leader in the field of contrast products, especially in medical imaging) as Financial Control Manager and in 2009 became Chief Executive Officer for Latin America, based in Brazil.

Since 2013, Alexis Peyroles has been involved in OSE Pharma, both as Chief Financial Officer and in charge of Business Development. From May 2016 (the date of the merger of OSE Pharma with Effimune) to April 2018, he served as Chief Operating Officer of OSE Immunotherapeutics, in charge of Finance, Business Development and Operations.

Alexis Peyroles graduated from EDHEC Business School and holds an Executive MBA from Imperial College in London.

Maryvonne Hiance specializes in nuclear science and served, for 14 years, as manager of neutron studies at FRAMATOME (Areva). Over a 20-year period, she held the position of General Manager at innovative biotechnology companies including SangStat Atlantic, DrugAbuse Sciences and TcLand. She also founded and served as General Manager of Strategic Ventures, a consulting company providing support to technological companies.

Maryvonne Hiance has been a member of the French Strategic Council for Innovation and has served as Advisor to the French SMEs and Industry Ministry.

In 2008, she co-founded and served as CEO for Effimune, a biotechnology company specialized in immune regulation with clinical applications in autoimmunity, transplantation and immuno-oncology. Since the merger of Effimune with OSE Pharma in 2016, she is Vice Chairman of the Board and Director for Public Affairs of OSE immunotherapeutics.

Maryvonne is Vice Chairman of France Biotech, the French Association of Life Sciences entrepreneurs.

Maryvonne Hiance holds an Engineering Degree from the Ecole Polytechnique Féminine (Paris) and a Nuclear Engineering Degree from Polytech Grenoble (formerly the Institut des Sciences et Techniques Grenoble).

Nicolas Poirier has been chief scientific officer of OSE Immunotherapeutics since 2016. He joined the company in 2009 as project leader and then as director of scientific programs. Nicolas holds a Ph.D. in immunology and has a strong expertise in the development of immunotherapies. His role at OSE has been to implement innovative therapeutic strategies on new targets and pathways in immunology addressing severe pathologies with high therapeutic need, thus making a robust contribution to the Company’s growth. Along with his R&D team, Dr. Poirier continues pursuing the identification of novel preclinical targets and translating them into first-class clinical-stage immunotherapies. He is the author of several high-level international publications in the area of immunotherapy.

Sophie Brouard is Director of Research at the Institut National de la Santé et Recherche Médicale (INSERM, National Institute for Health and Medical Research) in Nantes, and in charge of a research unit dedicated to transplantation and its mechanism. In parallel, Dr. Brouard serves as Director of the Centaure Foundation, a renowned foundation and pioneer in pancreas transplant. Centaure is also known worldwide for its research on immunological mechanisms of diabetes in experimental models, and in the conduct of clinical trials in diabetic patients. Sophie was a co-founder of Effimune and is the author of more than 130 peer-reviewed scientific publications, and currently holds 10 patents.
Sophie Brouard is a trained immunologist, Doctor in Veterinary Science and Transplant specialist. She has completed her postdoctoral degree at the Harvard Medical School in Boston.

Jean-Patrick Demonsang served as President and Managing Director of Seventure Partners (Paris based private equity fund) until 2013. During his career, he has supported the activities of more than 150 companies involved in the information technology and life sciences sectors. Jean-Patrick Demonsang is also an entrepreneur who has participated in the creation of a number of small- and medium-sized businesses. He is also at the root of the first club for start-ups.
Jean-Patrick Demonsang holds a MBA from the French business school HEC and a physics degree.

Brigitte Dréno, MD, PhD, is head of the Department of Dermatology at the Nantes University Hospital, a department with significant expertise in research and innovative treatments in skin oncology. She is the Director of the Biotherapy Clinical Investigation Centre, Director of the Unit of Cell and Gene Therapy and Vice Dean for Research Medical Faculty. Within her operational functions and research responsibilities, Dr. Dréno is very much involved in immuno-oncology innovation. In collaboration with the academic leadership, she supports the implementation of OSE Immunotherapeutics’ R&D initiatives on the Nantes University campus.

Dr. Didier Hoch, MD, has been working in the pharmaceutical and vaccine industries for 25 years. From 2000 to 2010, he was Chairman of Sanofi Pasteur MSD (European JV for vaccines between Sanofi Aventis & Merck), a leader in the European vaccines market. Previously, he held various functions internationally within Rhône Poulenc Rorer (then Aventis/Sanofi), including commercial, marketing and general management. Prior to that, Didier Hoch served as Vice President and President (2002 to 2010) of the European Vaccine Manufacturers Association (EVM) and as President of the LEEM Biotechnology Committee (2006 – 2009).

In 2014, Didier Hoch co-founded Big Booster, an international startups accelerator Program, he led until 2018. He is currently board member of several health companies, including Germitec and Myasterix/Curavac and of the University of the Underground Charity Foundation (Netherland).

Gérard Tobelem is a former haematology professor at Paris 7 University and former Head of the department of blood disorders at the Lariboisière hospital in Paris, as well as past Executive Chairman of the French Blood Establishment. Gérard Tobelem’s research work was recognized when, in 2006, he was awarded the first Diderot Innovation prize. He has practised strategic functions within the French Ministry of Higher Education and Research and has also advised different international pharmaceutical companies in their R&D strategies. Mr. Tobelem currently serves as non-executive Chairman of the Board of Directors of Theradiag.

Alexis Peyroles has more than 20 years of international management and financial control experience, having served in multiple related positions. He joined Sanofi-Aventis in 1996 as Financial Controller in Japan before becoming Head of Financial Control for the Baltic States. He was subsequently named Head of activities for Business Development in Eastern Europe. In 2005, Alexis joined the Guerbet group (a leader in the field of contrast products, especially in medical imaging) as Financial Control Manager and in 2009 became Chief Executive Officer for Latin America, based in Brazil.

Since 2013, Alexis Peyroles has been involved in OSE Pharma, both as Chief Financial Officer and in charge of Business Development. From May 2016 (the date of the merger of OSE Pharma with Effimune) to April 2018, he served as Chief Operating Officer of OSE Immunotherapeutics, in charge of Finance, Business Development and Operations.

Alexis Peyroles graduated from EDHEC Business School and holds an Executive MBA from Imperial College in London.

With more than 25 years of experience in management positions in the pharmaceutical industry (HMR, now Sanofi), Dr. Dominique Costantini has overseen many therapeutic innovations and was involved in the development of numerous medicines, from conception to product approval and commercialisation (notably in immunology, oncology, endocrinology and infectious illnesses).

In 1997, Dominique Costantini founded and led as CEO BioAlliance Pharma (now Onxeo), a biotech company in oncology and supportive care; in 2005, she conducted the company’s IPO on Euronext and the registration of products in Europe and the US.

In 2012, Dominique founded and was CEO of OSE Pharma, a biotech company in cancer immunotherapy. In 2015, she conducted the company’s IPO on Euronext and in 2016 its merger with Effimune, a biotechnology company specialized in immune regulation. Dominique served as CEO and Director of the company, since renamed OSE Immunotherapeutics until April 2018.

Dr. Dominique Costantini is a Medical Doctor (Paris V University), specializing in immunology.

Maryvonne Hiance specializes in nuclear science and served, for 14 years, as manager of neutron studies at FRAMATOME (Areva). Over a 20-year period, she held the position of General Manager at innovative biotechnology companies including SangStat Atlantic, DrugAbuse Sciences and TcLand. She also founded and served as General Manager of Strategic Ventures, a consulting company providing support to technological companies.

Maryvonne Hiance has been a member of the French Strategic Council for Innovation and has served as Advisor to the French SMEs and Industry Ministry.

In 2008, she co-founded and served as CEO for Effimune, a biotechnology company specialized in immune regulation with clinical applications in autoimmunity, transplantation and immuno-oncology. Since the merger of Effimune with OSE Pharma in 2016, she is Vice Chairman of the Board and Director for Public Affairs of OSE immunotherapeutics.

Maryvonne is Vice Chairman of France Biotech, the French Association of Life Sciences entrepreneurs.

Maryvonne Hiance holds an Engineering Degree from the Ecole Polytechnique Féminine (Paris) and a Nuclear Engineering Degree from Polytech Grenoble (formerly the Institut des Sciences et Techniques Grenoble).

Dr. Frédérique Corallo has more than 25 years of global experience in the pharmaceutical and biotechnology industries. Prior to joining OSE Immunotherapeutics, she spent more than 10 years as Medical Director at Biogen, one of the world’s leading biotechnology companies.

Frédérique previously held management positions in Medical Affairs and Clinical Research at multiple biopharmaceutical companies, including Janssen Cilag and Sanofi (Hoechst Marion Roussel). Throughout her career, she has led strategic and operational management of immunology-related clinical development programs and medical marketing activities.

Frédérique Corallo is a Medical Doctor, specializing in immunology.

Nicolas Poirier has been chief scientific officer of OSE Immunotherapeutics since 2016. He joined the company in 2009 as project leader and then as director of scientific programs. Nicolas holds a Ph.D. in immunology and has a strong expertise in the development of immunotherapies. His role at OSE has been to implement innovative therapeutic strategies on new targets and pathways in immunology addressing severe pathologies with high therapeutic need, thus making a robust contribution to the Company’s growth. Along with his R&D team, Dr. Poirier continues pursuing the identification of novel preclinical targets and translating them into first-class clinical-stage immunotherapies. He is the author of several high-level international publications in the area of immunotherapy.

Dr. Bérangère Vasseur has over 20 years of experience in clinical development in biotechnology and pharmaceutical companies, specializing in innovative molecules in oncology.

Before joining OSE Immunotherapeutics, she has spent 10 years at Roche Pharma where she has worked on medico-marketing strategies for the registration of cancer treatments. She has also been head of clinical development in biotechnology companies specializing in orphan cancer treatments.

Bérangère Vasseur is a Medical Doctor.

Emilienne Soma specializes in the development of drug products with innovative dosing regimens in various therapeutic areas including oncology, infectious diseases and HIV. She has over 20-years of experience in biotechnology companies where she led and coordinated the pharmaceutical development of biotherapies, nanomedicine products and new chemical entities. Throughout her career, Emilienne has acquired extensive expertise in R&D and alliance management.
Emilienne Soma holds a PhD in Pharmacy and a Doctorate in Science.

Jean-Pascal Conduzorgues serves as Qualified Person, a pharmaceutical leadership role required for medicines in Europe. Jean-Pascal is the founder of CRID Pharma, specializing in pharmaceutical development and organization of clinical trials in Montpellier, which he has managed for 20 years. In 2011, he merged CRID Pharma with Avogadro to create and manage Amatsi group, a contract development and manufacturing organization based in France and in the U.S. In 2013, Jean-Pascal In 2013, Jean-Pascal created his own consultant company, Ibero, and as such joined OSE to bring his expertise in pharmaceutical and drug developement strategy for clinical trials and commercialization.
Jean-Pascal Conduzorgues is Doctor in Pharmacy and QP

Specialized in Audit-Finance, Anne-Laure has acquired a seven-year experience within Deloitte before joining Effimune in 2013 as Administrative and Financial Manager. Upon the merger with OSE Pharma in 2016, Anne-Laure was appointed Chief Financial Officer of OSE Immunotherapeutics.

Anne-Laure Autret-Cornet graduated from ESSCA Management school and has received the certificate “Corporate Finance” from HEC Paris in 2020.